Amphora Sells Oncology Program to Genentech
Amphora Discovery Corporation announced that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology indications. Other terms of the agreement were not disclosed. Under the terms of the agreement, Genentech acquired all of the intellectual property for the program, including the preclinical lead and several backup series.
"We are delighted that Genentech sees the potential value of one of our early stage programs," said C. Nicholas Hodge, Ph.D., Amphora's CSO and founder. "I personally see this as validation of our ability to produce high quality drug candidates."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.